BMY vs Peers Stock Comparison

Bristol Myers Squibb Prices as of Oct 26, 2026 Peers: Industry group
BMY Bristol Myers Squibb Co
$61.61 -2.0% 1M +40.6% 1Y
Market cap
$125.86B
P/E
13.6x
Revenue (TTM)
$49.19B
Div. yield
–
Pharmaceuticals Healthcare

Percentile Scorecard

BMY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisBMY
Valuation 86 #90 of 626
Growth 52 #291 of 604
Profitability 87 #75 of 555
Financial Health 16 #552 of 658
Shareholder Returns 88 #45 of 368
Overall 66
  • BMY ranked among 673 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodBMYSPY
1 month -2.0% -0.8%
3 months -1.5% +3.5%
6 months +6.6% +7.0%
Year to date +14.2% +12.2%
1 year +40.6% +13.0%
3 years +20.8% +86.3%
3 years, per year +6.5% +23.1%
5 years +9.1% +68.6%
5 years, per year +1.8% +11.0%
10 years +25.0% +258.0%
10 years, per year +2.3% +13.6%

Risk

MeasureBMYSPY
Volatility, 1Y 28.4% 12.7%
Downside volatility, 1Y 25.6% 12.7%
Beta vs S&P 500, 1Y 0.20 1.00
Return / volatility, 1Y 1.43 1.02
Max drawdown, 5Y -51.1% -25.4%
From 52-week high -9.5% -1.8%
52-week high $68.09 $779.14
52-week low $42.60 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleBMY
P/E now vs peer median 13.6xmedian 17.1x
P/S now vs peer median 2.6xmedian 8.8x
EV/EBITDA now vs peer median 388.9xmedian 17.1x
P/FCF now vs peer median 11.0xmedian 18.0x
P/B now vs peer median 5.6xmedian 2.1x
PEG now vs peer median 2.20median 0.31

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsBMY
Revenue $49.19B
Gross profit $34.51B
Operating income -$2.77B
Net income $9.28B
Free cash flow $11.44B
R&D $10.72B
EPS (diluted) $4.53
Cash & equivalents $8.72B
Total debt $43.12B
Shares (diluted) 2.05B
Enterprise value $77.13B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricBMY
P/E 13.6x
P/FCF 11.0x
P/Operating cash flow 9.8x
P/S 2.6x
P/B 5.6x
P/Tangible book 25.5x
EV/EBITDA 388.9x
EV/EBIT -57.0x
EV/Revenue 3.2x
EV/FCF 13.8x
EV/Operating cash flow 12.4x
PEG (3Y EPS CAGR) 2.20

Growth

14 metrics
MetricBMY
Revenue growth (1Y) 3.1%
Revenue CAGR (3Y) 2.9%
Gross profit growth (1Y) 2.9%
Gross profit CAGR (3Y) -0.3%
Operating income growth (1Y) 63.5%
Operating income CAGR (3Y) -17.9%
Net income growth (1Y) 83.3%
Net income CAGR (3Y) 5.2%
EPS growth (1Y) 82.9%
EPS CAGR (3Y) 6.2%
Operating cash flow growth (1Y) -19.6%
Operating cash flow CAGR (3Y) 2.6%
Free cash flow growth (1Y) -21.5%
Free cash flow CAGR (3Y) 2.2%

Profitability

14 metrics
MetricBMY
Gross margin 70.2%
EBITDA margin 0.8%
Operating margin -5.6%
Pretax margin 24.2%
Net margin 18.9%
FCF margin 23.3%
Operating cash flow margin 26.0%
Return on equity 43.7%
Return on assets 10.7%
Return on invested capital -3.3%
Return on capital employed -4.0%
Asset turnover 0.6x
Cash conversion (OCF / net income) 1.4x
Stock comp / revenue 1.1%

Financial Health

11 metrics
MetricBMY
Debt / assets 49.2%
Debt / equity 1.9x
Net debt / EBITDA 78.9x
Debt / FCF 3.8x
Liabilities / assets 74.5%
Equity / assets 25.5%
Interest coverage –
Current ratio 1.5x
Quick ratio 1.2x
Cash ratio 0.6x
Altman Z-score 2.07

Shareholder Returns

7 metrics
MetricBMY
Dividend yield 4.1%
Net buyback yield –
Shareholder yield 4.1%
Payout ratio (earnings) –
Payout ratio (FCF) –
Dividend growth (1Y) –
Dividend CAGR (3Y) –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusBMY
Forward P/E 9.3xFY2026
EPS, next fiscal year $6.63FY2026
EPS growth, next FY +7.8%FY2026
EPS growth, the year after -3.9%
Revenue, next fiscal year $52.09BFY2026
Revenue growth, next FY +8.1%FY2026
Revenue growth, the year after -9.3%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersBMY
Held by institutions 81.8%
Institutions holding 2,519
Change in shares held, QoQ +3.8%
Institutions buying 1,185
Institutions selling 986
Buyers to sellers 1.20

Add a Peer

Largest companies in the same industry

Related Comparisons

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.